Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 3,501–3,600 of 4,628
Targeting sorting nexin 3 to treat pulmonary fibrosis by dual modulating Wnt/β-catenin signaling
Ma, D., Yu, W., Zhou, H., Lin, R., Sun, X., Peng, M., Lin, C., Du, H., Li, Y., Liang, H., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-025-08248-x · Cited by 1
Trboljevac, N., Dimić-Janjić, S., Kontić, M., Omčikus, M., Ilić, B., Marković, F., Postic, A., Isovic, L., Stjepanović, M., & Nenezic, D. (2026) · Medicina · doi:10.3390/medicina62010229 · Cited by 1
“The extent of FVC decline in our cohort matches that observed in the ASCEND and INPULSIS trials, supporting the external validity of our real-world results [15,16].”
Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management
Joshua, J., & Borok, Z. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-050224-121458 · Cited by 2
Chen, L., Lan, C., Deng, X., Wu, M., Shao, M., Yang, M., Ma, X., Huang, F., & Wu, H. (2026) · Canadian Respiratory Journal · doi:10.1155/carj/6614209 · Cited by 1
The human pathome shows sex and tissue specific aging patterns
Ezra, M. B., Garbrecht, J. B., Rasmussen, N., Mediavilla, M. C., Heckenbach, I., Petr, M. A., Bakula, D., Mortensen, L. H., & Scheibye‐Knudsen, M. (2026) · npj Aging · doi:10.1038/s41514-025-00307-z · Cited by 2
Sethi, P. P., Gupta, A. K., Sudan, A., Baweja, A., Ranka, R., Khapre, M. P., Manna, S., Kant, R., & Pai, V. S. (2026) · Indian Journal of Rheumatology · doi:10.1177/09733698251403238 · Cited by 1
A case of membranoproliferative glomerulonephritis-type IgA nephropathy modified by nintedanib
Kunisho, Y., Sofue, T., Nagano, H., Higashitani, M., Shiga, T., Shiraishi, A., Aoki, Y., Onishi, K., Ibuki, E., & Minamino, T. (2026) · CEN Case Reports · doi:10.1007/s13730-025-01066-2 · Cited by 1
Mariniello, D. F., Perrotta, F., Picone, C., Liakouli, V., Zamparelli, S. S., Stella, G. M., Reginelli, A., Rea, G., Bianco, A., & D’Agnano, V. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1741725 · Cited by 1
“However, two antifibrotic agents, nintedanib and pirfenidone, have been approved for the treatment of IPF, as they have been shown to slow the rate of lung function decline (3–5).”
Idiopathic Pulmonary Fibrosis: An Overview
May, J., & Jenkins, G. R. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm50844 · Cited by 3
Lei, S., Li, J., Yang, T., Peng, Z., Xu, Y., Hui, Z., Yan, M., Feng, C., Liu, H., & Tang, W. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178707 · Cited by 2
Almalki, R. S. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s570825 · Cited by 1
Ni, Y., Shen, H., Lee, C.-Y., Lee, T. P., Sieber, M. A., Tseng, C.-C., Tsao, C.-Y. T., & Kuan, Y. (2026) · Open Life Sciences · doi:10.1515/biol-2025-1293 · Cited by 3
Cooley, J. C., Penick, S. K., Wilson, J. A., Javkhlan, N., Foster, D. G., Edelman, B., Schott, C. A., Humphries, S. M., Lynch, D. A., Schwartz, D. A., et al. (2026) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1093/ajrcmb/aanag045 · Cited by 1
Bazsó, A., Szodoray, P., Shoenfeld, Y., Nagy, G., & Kiss, E. V. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104035 · Cited by 1
Boutel, M., Skouvaklidou, E. C., Partalidou, S., Boutou, A., Antoniou, K. M., Katsigianni, I., Adamichou, C., & Dimitroulas, T. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104036 · Cited by 1
Kim, G. H. J., Woodhead, F. A., Nair, D., Bao, H., Lazarus, H. M., Conoscenti, C. S., & Goldin, J. G. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04234-x · Cited by 1
Okuda, R., Nishioka, Y., Kondoh, Y., Tsubouchi, K., Okamoto, M., Nishiyama, O., Sato, S., Oishi, K., Ishikawa, N., Chiba, H., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag125 · Cited by 1
Self-citationSong, D., Yang, Y., Li, Z., Song, L., An, B., Yuan, Z., Liu, Y., Su, R., Guo, W., & Xie, L. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100370 · Cited by 2
Geriatric nutritional risk index in antifibrotic therapy can predict tolerability and mortality risk
Masuda, T., Mochizuka, Y., Suzuki, Y., Kono, M., Matsushima, S., Kato, S., Suzuki, K., Tanaka, K., Koda, K., Masuda, T., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-45792-8 · Cited by 1
Self-citationFermoyle, C. C., Mackintosh, J. A., Navaratnam, V. V., Ellis, S. J., Cooper, W. A., Goh, N. S. L., Moodley, Y. P., Reynolds, P. N., Zappala, C. J., Hopkins, P. M.-A., et al. (2026) · Respirology · doi:10.1002/resp.70246 · Cited by 4
“Such variability in diagnosis has significant implications for management decisions and clinical trial enrolment for patients with fibrotic lung disease [3, 4].”
Brugière, O., Hirschi, S., Reynaud‐Gaubert, M., Bunel, V., Demant, X., Pavec, J. L., Falque, L., Mohammed, N. S., Tardivon, C., & Couffignal, C. (2026) · Trials · doi:10.1186/s13063-025-09314-7 · Cited by 1
Xia, Y., Zhou, F., Ma, B., Gong, H., Jing, M., Dai, L., & Ouyang, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1789907 · Cited by 1
The immunodynamics of pulmonary fibrosis
Xie, C. H., Ma, Y., Wang, Y., Gul, A., Tang, W., Luo, Q., Xu, W., Wei, Y., Dong, J., & Liu, W. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.04.001 · Cited by 1
Respiratory oscillometry identifies disease progression in interstitial lung disease
Dubé, R., Duran, O. A., Azuelos, I., Cormier, M., Dandurand, R. J., & Assayag, D. (2026) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2025-003900 · Cited by 4
Kasamatsu-Nishimura, T., Kitabatake, M., Ouji-Sageshima, N., Akiyama, Y., Furukawa, R., Saito, S., Hara, A., Kumamoto, M., Hontsu, S., Kawaguchi, T., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101424 · Cited by 1
Rosas, I. O., McDowell-Sanchez, A. K., Sanchez, S., Cala-García, J., Cohen, A. R. W., Ruiz-Echartea, E., Ochsner, S. A., Kraushaar, D. C., Celada, L. J., Sun, D., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci197651 · Cited by 4
Elastokines are potentially associated with a poor prognosis in idiopathic pulmonary fibrosis
Nagel, D. J., Okutani, T., Lopa, S., Mariani, T. J., Sime, P. J., Kottmann, R., & Hocking, D. C. (2026) · Scientific Reports · doi:10.1038/s41598-026-51836-w · Cited by 3
C/EBPγ interacts with C/EBPα and activates the β-catenin pathway in idiopathic pulmonary fibrosis
Pan, X., Xia, C., Gan, Y., Cao, Y., Zhao, M., Liu, H., Zhou, Y., Wang, Y., Li, Z., Li, B., et al. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06245-7 · Cited by 1
Kim, D. Y., Kim, M.-J., Jin, Y. R., Hwang, H. J., Chae, E. J., Lee, S. M., Park, S., Lee, J. C., Seo, J. B., Lee, H. Y., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag245 · Cited by 1
Self-citationTirelli, C., Muscato, G., Alaimo, C., Leo, I. D., Mirijaj, S., Pennisi, F., Vancheri, C., & Mondoni, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114172 · Cited by 2
“It is an intracellular tyrosine kinase inhibitor targeting receptors for PDGF, VEGF and fibroblast growth factor (FGF), all of which participate in fibroblast activation, migration, and myofibroblast differentiation [4,33,62].”
InfluentialHolistic management of symptom burden in fibrosing interstitial lung diseases (F-ILDs)
Krishna, R. V., & Lindell, K. O. (2026) · Thorax · doi:10.1136/thorax-2024-222056 · Cited by 1
Performance of age-adjusted whole genome sequencing telomere length in idiopathic pulmonary fibrosis
Kim, J. S., Receveur, B. A., Zhang, D., Ma, S.-F., Huang, Y., McGroder, C. F., Putman, R. K., Podolanczuk, A. J., Rotter, J. I., Rich, S. S., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag259 · Cited by 1
Self-citationShuto, H., Hagiwara, A., Kudoh, R., Matsumoto, H., Omori, S., Fushimi, K., & Komiya, K. (2026) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2026.101293 · Cited by 1
Öcal, N., Balcan, B., & Peker, Y. (2026) · Sleep Medicine X · doi:10.1016/j.sleepx.2026.100191 · Cited by 2
“Anti-fibrotic agents such as nintedanib and pirfenidone slow disease progression but may exacerbate gastrointestinal discomfort or disrupt sleep, necessitating monitoring [63].”
Honap, S., Dignass, A. U., Jairath, V., et al. (2026) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2026.2695461 · Cited by 1
Miao, Y., Hu, Y. Q., Xu, L., Xu, L., Meng, L., Yang, Y., Liu, Z., Yang, Z., Liu, Y.-M., Liu, Y., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118204 · Cited by 1
Diagnosis and treatment of idiopathic pulmonary fibrosis: a narrative review
Yoo, J. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0044 · Cited by 1
Definition and diagnostic approach to interstitial lung disease: a narrative review
Kim, K. H. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0049 · Cited by 1
Álvarez-Muro, L., Collado-Jiménez, M., Hoyas-Sánchez, C., et al. (2026) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2026.06.016 · Cited by 1
Mycophenolate and azathioprine in fibrotic interstitial lung disease
Pugashetti, J. V., Jee, A. S., Yu, A. R. M., Hammoud, N., Chua, F., Yazbeck, L., Lee, C. T., Liu, G. Y., Adams, T. N., Adegunsoye, A., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag362 · Cited by 3
Li, Y., Song, W., Huan, C., Xu, K., Sun, J., Zhen, X., Ouyang, H., Tang, H., Fan, Q., Zhi, W., et al. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109089 · Cited by 3
Oh, J. H., Song, J. W., Goldin, J. G., WEIGT, S. S., Chung, A., Wilkinson, J. D., Abtin, F. G., Pourzand, L., Villegas, B. E., Lee, J., et al. (2026) · Respirology · doi:10.1002/resp.70299 · Cited by 1
Bernardi, E., Mitchell, W., Troyas, C., & Anguita, R. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2724125 · Cited by 1
Furuto, Y., Hashimoto, H., Yoshino, D., et al. (2026) · Nephrology · doi:10.1111/nep.70274 · Cited by 1
Yang, M. H., Kim, S., Lee, S. M., Yun, J., Hwang, H. J., Chae, E. J., Seo, J. B., Choe, J., & Kim, H. C. (2026) · Radiology · doi:10.1148/radiol.260703 · Cited by 1
Forrest, I., & Peel, E. T. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2230-2_9 · Cited by 1
Nintedanib in idiopathic pulmonary fibrosis: a guide to its use
Keating, G. M. (2015) · Drugs & Therapy Perspectives · doi:10.1007/s40267-015-0240-y · Cited by 1
Therapeutische Relevanz des HRCT-Befundes aus pneumologischer Sicht
Suchy, R., & Pfeifer, M. A. (2014) · Der Radiologe · doi:10.1007/s00117-014-2739-y · Cited by 1
A new era of drug therapy for idiopathic pulmonary fibrosis
Crooks, M. G., & Hart, S. P. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70257-7 · Cited by 1
Clinical highlights: messages from Munich
Vogiatzis, I., Marvisi, M., Coolen, J., et al. (2015) · ERJ Open Research · doi:10.1183/23120541.00002-2015 · Cited by 1
Lung transplantation for interstitial lung disease
Paoletti, L., & Whelan, T. P. M. (2014) · Current Respiratory Care Reports · doi:10.1007/s13665-014-0083-3 · Cited by 1
Transcriptional phenotyping of fibrotic lung disease: a new gold standard?
Maher, T. M. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00184-8 · Cited by 1
Eapen, M. S., Shukla, S., Mahmood, M., McAlinden, K. D., Eri, R. D., Walters, E. H., & Sohal, S. S. (2015) · eCite Digital Repository (University of Tasmania) · Cited by 1
Mesenchymal Stromal Cell-Based Therapies for Lung Disease
Chambers, D. C. (2015) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-319-21082-7_14 · Cited by 1
Idiopathic pulmonary fibrosis can be a transient diagnosis
de Oliveira, M. R., Pereira, D. A. S., Dias, O. M., et al. (2016) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37562016000000003 · Cited by 1
To Suppress the Radicals We Must Have Biomarkers of Oxidative Stress
Jenkins, G. R. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201511-2311ed · Cited by 1
Deux traitements efficaces pour la fibrose pulmonaire idiopathique : une nouvelle ère commence !
Crestani, B. (2015) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2015.05.011 · Cited by 1
Emerging Therapies for Progressive Metastatic Medullary Thyroid Cancer
Zwiener, J. E., Kwatampora, L. J., & Busaidy, N. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-39412-1_17 · Cited by 1
The Role of Mesenchymal Stromal Cells in Idiopathic Pulmonary Fibrosis
Río, C. (2016) · International Journal of Stem cell Research & Therapy · doi:10.23937/2469-570x/1410030 · Cited by 1
Translating Autoimmune Pathogenesis into Targeted Therapies for Systemic Sclerosis
Russell, M., & Sofat, N. (2017) · InTech eBooks · doi:10.5772/66642
Staging of idiopathic pulmonary fibrosis
Kishaba, T. (2017) · International Journal of Current Advanced Research · doi:10.24327/ijcar.2017.3011.0164
Pathobiology of Novel Approaches to Treatment
Puglisi, S., & Vancheri, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00002-1 · Cited by 1
Patient-centered Outcomes in Idiopathic Pulmonary Fibrosis Clinical Trials
Podolanczuk, A. J., & Lederer, D. J. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201705-0975ed · Cited by 1
The Hospitalized Patient with Interstitial Lung Disease: A Hospitalist Primer
Farrand, E. D., Shah, R., & Collard, H. R. (2017) · Journal of Hospital Medicine · doi:10.12788/jhm.2774 · Cited by 1
Self-citationIdiopathic Pulmonary Fibrosis-Unknown Cause, Global Occurrence and New Medical Possibilities
Roskova, E., Solovič, I., & Matula, B. (2018) · Internal Medicine Open Access · doi:10.4172/2165-8048.1000272 · Cited by 1
Chronic Lung Allograft Dysfunction: Phenotypes and the Future
Chambers, D. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-90933-2_11 · Cited by 2
Fibrostenotic Inflammatory Bowel Disease: A Cinderella Story
Rieder, F. (2018) · Springer eBooks · doi:10.1007/978-3-319-90578-5_1 · Cited by 1
New era of Idiopathic Pulmonary Fibrosis
Kishaba, T. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.08.008 · Cited by 1
Complications of Transbronchial Cryobiopsy
Ravaglia, C. (2019) · Springer eBooks · doi:10.1007/978-3-030-14891-1_6 · Cited by 1
Idiopathic Pulmonary Fibrosis as a Challenge for the Polish Healthcare System
Kwiecień, M., Budasz-Świderska, M., & Kaczor, M. (2015) · Journal of Health Policy & Outcomes Research · doi:10.7365/jhpor.2015.2.1
Acute exacerbations in IPF: A clarion call for collaborative research
Glaspole, I. (2020) · Respirology · doi:10.1111/resp.13770 · Cited by 1
Guías chilenas de fibrosis pulmonar idiopática, 2019
P, Á. U. (2019) · Revista chilena de enfermedades respiratorias · doi:10.4067/s0717-73482019000400254 · Cited by 1
Gläser, S., Glöckl, R., & Bonella, F. (2020) · Der Pneumologe · doi:10.1007/s10405-020-00313-w · Cited by 1
Management of Idiopathic Pulmonary Fibrosis
Cerri, S., Spagnolo, P., Luppi, F., Sgalla, G., & Richeldi, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00004-5 · Cited by 1
Self-citationIdiopathic Interstitial Pneumonias
Homer, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-39308-9.00016-9 · Cited by 1
A new therapy for systemic sclerosis-associated interstitial lung disease
Kondoh, Y. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.03.005 · Cited by 1
Ikeda, S., Ogura, T., Kato, T., Kenmotsu, H., Iwasawa, T., Misumi, T., Yamanaka, T., & Okamoto, H. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920923431 · Cited by 1
Yadav, A., Prateek, S., Chawla, L., et al. (2020) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2020/640 · Cited by 1
Current advances in the treatment of autoimmune-associated interstitial lung diseases
Lee, S., & Lee, J. H. (2021) · Journal of Korean Medical Association · doi:10.5124/jkma.2021.64.4.264 · Cited by 1
Treatment of idiopathic pulmonary fibrosis with an extracellular vesicle isolate product
Bligh, R. (2021) · International Journal of Science and Research Archive · doi:10.30574/ijsra.2021.2.2.0060 · Cited by 4
Update in Diagnosis of Idiopathic Pulmonary Fibrosis and Interstitial Lung Abnormality
Nam, B. D., & Hwang, J. H. (2021) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2021.0072 · Cited by 2
Mortality differences in pulmonary fibrosis among the most populated states in the United States
Jeganathan, N., & Sathananthan, M. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106565 · Cited by 2
Feshchenko, Y. I., Gavrysyuk, V. K., Горовенко, Н. Г., Dziublyk, Y., & Liskina, I. V. (2021) · Ukrainian Pulmonology Journal · doi:10.31215/2306-4927-2021-29-3-5-23 · Cited by 2
Interstitial lung disease and rheumatoid arthritis
Atzeni, F., Siragusano, C., & Gómez-Puerta, J. A. (2022) · Technical report · doi:10.1016/b978-0-323-91083-5.00010-4 · Cited by 1
Prasse, A. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10005615 · Cited by 1
New Lung Imaging Findings in Chronic Respiratory Diseases
Ash, S. Y., & Washko, G. R. (2017) · Barcelona Respiratory Network · doi:10.24875/brn.m17000011 · Cited by 1
Let's talk about sex in interstitial lung disease
Grant-Orser, A., & Johannson, K. A. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00253-3 · Cited by 1
de Andrade, J. A., Luckhardt, T., Sonavane, S. K., Crowe, D. R., Kulkarni, T., Lara, M. D. P. A., Gulati, S., Il-Kim, Y., Ramachandran, R., & O'Beirne, R. (2023) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v40i1.11460 · Cited by 2
Caminati, A., Inas, A. W. A. D., Elia, D., Cassandro, R., Mozzanica, F., Pelosi, G., Zompatori, M., & Harari, S. A. (2023) · Minerva Medica · doi:10.23736/s0026-4806.23.08720-7 · Cited by 1
Brown, S.-A. W., & Braman, S. S. (2023) · Springer eBooks · doi:10.1007/978-3-030-01782-8_55-1 · Cited by 2
Matson, S. M., & Lee, J. S. (2023) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2023.07.002 · Cited by 1
Idiopathic Interstitial Pneumonias
Barış, S. A., Başyiğit, İ., & Nathan, S. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-22483-6_88-1 · Cited by 1
Algorithmic approach in the management of COVID-19 patients with residual pulmonary symptoms
Guri, A., Groner, L. K., Escalon, J. G., & Saleh, A. G. (2023) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_83_23 · Cited by 1
Sinha, L., & Karmakar, S. (2023) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-99-4939-7_15 · Cited by 1
Pulmonary fibrosis treatment in children – What have we learnt from studies in adults?
Jia, M. B., & Fitzgerald, D. A. (2023) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2023.12.001 · Cited by 3
Şenel, A. S., Denizhan, T. K., Kızıltepe, M., et al. (2023) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v40i4.14716 · Cited by 1
Üzer, F., AKANLAR, S., & Çilli, A. (2023) · Tuberkuloz ve Toraks · doi:10.5578/tt.20239603 · Cited by 4
Brown, S.-A. W., & Braman, S. S. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_55 · Cited by 1
DESAFIOS E PERSPECTIVAS NA GESTÃO DA FIBROSE PULMONAR IDIOPÁTICA: RUMO A TERAPIAS MAIS EFICAZES
Silva, A. S., Bomfim, V. V. B. D. S., Brito, I. R. A. X., Bucciaroni, R., Oliveira, P. M. R. E., Bezerra, B. W. W., Costa, L. M. M., & Neto, H. J. R. (2024) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v10i4.13558 · Cited by 1
Anti-synthase syndrome associated with SARS-Cov-2 infection
Chen, X., Chen, J., Zhi, L.-J., et al. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02966-2 · Cited by 1
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.